Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Nivolumab is an immune checkpoint inhibitor (ICI) currently undergoing Phase III clinical trials for the treatment of glioblastoma. The authors present the case of a 10-year-old girl with glioblastoma treated with nivolumab under compassionate-use guidelines. After the first dose of nivolumab the patient developed hemiparesis, cerebral edema, and significant midline shift due to severe tumor necrosis. She was managed using intravenous dexamethasone and discharged on a dexamethasone taper. The patient's condition rapidly deteriorated after the second dose of nivolumab, demonstrating hemiplegia, seizures, and eventually unresponsiveness with a fixed and dilated left pupil. Computed tomography of her brain revealed malignant cerebral edema requiring emergency decompressive hemicraniectomy. Repeat imaging demonstrated increased size of the lesion, reflecting immune-mediated inflammation and tumor necrosis. The patient remained densely hemiplegic, but became progressively more interactive and was ultimately extubated. She resumed nivolumab several weeks later, but again her condition deteriorated with headache, vomiting, swelling at the craniectomy site, and limited right-sided facial movement following the sixth dose. MRI demonstrated severe midline shift and uncal herniation despite her craniectomy. Her condition gradually declined, and she died several days later under “do not resuscitate/do not intubate” orders. To the authors' knowledge, this represents the first case of malignant cerebral edema requiring operative intervention following nivolumab treatment for glioblastoma in a pediatric patient.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Aoyama, H., Shirato, H., Tago, M., Nakagawa, K., Toyoda, T., Hatano, K., Kenjyo, M., Oya, N., Hirota, S., Shioura, H., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2483 · Cited by 2,213
The Definition of Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3002 · Cited by 1,132
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Motzer, R. J., Rini, B. I., McDermott, D. F., Redman, B. G., Kuzel, T. M., Harrison, M. R., Vaishampayan, U. N., Drabkin, H. A., George, S., Logan, T. F., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0703 · Cited by 1,074
Microsatellite Instability as a Biomarker for PD-1 Blockade
Dudley, J. C., Lin, M.-T., Le, D. T., & Eshleman, J. R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1678 · Cited by 931
Bouffet, E., Larouche, V., Campbell, B. B., Merico, D., de Borja, R., Aronson, M., Durno, C., Krueger, J., Cabric, V., Ramaswamy, V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6552 · Cited by 857
Self-citationCohen, K. J., Pollack, I. F., Zhou, T., Buxton, A., Holmes, E. J., Burger, P. C., Brat, D. J., Rosenblum, M. K., Hamilton, R. L., Lavey, R. S., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq191 · Cited by 399
Kiess, A. P., Wolchok, J. D., Barker, C. A., Postow, M. A., Tabar, V., Huse, J. T., Chan, T. A., Yamada, Y., & Beal, K. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.01.004 · Cited by 390
Prospects of immune checkpoint modulators in the treatment of glioblastoma
Preusser, M., Lim, M., Hafler, D. A., Reardon, D. A., & Sampson, J. H. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.139 · Cited by 388
Ahmed, K. A., Stallworth, D. G., Kim, Y., Johnstone, P. A. S., Harrison, L. B., Caudell, J. J., Yu, H. H. M., Etame, A. B., Weber, J. S., & Gibney, G. T. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv622 · Cited by 239
Koelzer, V. H., Rothschild, S. I., Zihler, D., Wicki, A., Willi, B., Willi, N., Voegeli, M., Cathomas, G., Zippelius, A., & Mertz, K. D. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0117-1 · Cited by 200
Pediatric High Grade Glioma: a Review and Update on Tumor Clinical Characteristics and Biology
Fangusaro, J. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00105 · Cited by 183
Hodi, F. S., Oble, D. A., Drappatz, J., Velazquez, E. F., Ramaiya, N., Ramakrishna, N., Day, A. L., Kruse, A., Rae, S. M., Hoos, A., et al. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1183 · Cited by 167
Treatment of high-grade glioma in children and adolescents
MacDonald, T. J., Aguilera, D., & Kramm, C. M. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor092 · Cited by 153
Weber, J. S., Amin, A., Minor, D. R., Siegel, J., Berman, D., & O'Day, S. J. (2011) · Melanoma Research · doi:10.1097/cmr.0b013e32834d3d88 · Cited by 114
Long-term outcomes in children with glioblastoma
Song, K. S., Phi, J. H., Cho, B.-K., Wang, K., Lee, J. Y., Kim, D. G., Kim, I. H., Ahn, H. S., Park, S., & Kim, S. (2010) · Journal of Neurosurgery Pediatrics · doi:10.3171/2010.5.peds09558 · Cited by 84
Sampson, J. H., Vlahovic, G., Sahebjam, S., Omuro, A. M. P., Baehring, J. M., Hafler, D. A., Voloschin, A. D., Paliwal, P., Grosso, J. F., Coric, V., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3010 · Cited by 70
Cited by
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Marcus, L., Lemery, S. J., Keegan, P., & Pazdur, R. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4070 · Cited by 1,176
“A concern raised during the reviewof the application resulted in a requirement to conduct assessment of safety and activity in pediatric patients with central nervous system (CNS) malignancies, givenpublished literature reports of antitumor responses and cerebral edema following checkpoint inhibition (a different PD-1…”
BackgroundSong, Y., Fu, Y., Xie, Q., Zhu, B., Wang, J., & Zhang, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01956 · Cited by 261
Harnessing the immune system in glioblastoma
Brown, N. F., Carter, T. J., Ottaviani, D., & Mulholland, P. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0258-8 · Cited by 223
Eranki, A., Srinivasan, P., Ries, M., Kim, A., Lazarski, C. A., Rossi, C. T., Khokhlova, T. D., Wilson, E., Knoblach, S. M., Sharma, K. V., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1604 · Cited by 179
Metadata
- Authors
- Zhu, X., McDowell, M. M., Newman, W. C., Mason, G. E., Greene, S., & Tamber, M. S.
- Affiliations
- Department of Neurological Surgery, and
- University of Pittsburgh (US)
- Corresponding author
- McDowell, Michael M.
- Venue
- Journal of Neurosurgery: Pediatrics
- Published
- 2017-02
- Volume
- 19
- Issue
- 2
- Pages
- 249-253
- ISSN
- 1933-0707 (ISSN-L)
- 1933-0715
- OpenAlex
- W2555536348
- Cited by
- 53
- References
- 17
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 4 · 2022: 5 · 2021: 7 · 2020: 4 · 2019: 9 · 2018: 13 · 2017: 8
- FWCI
- 7.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Neurosurgery Pediatrics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Brain Metastases and Treatment
- Keywords
- nivolumab, pediatric glioblastoma, immune checkpoint inhibitors, immune-related adverse events, malignant cerebral edema, tumor necrosis, decompressive hemicraniectomy, midline shift, uncal herniation, hemiparesis, seizures, dexamethasone
- MeSH terms
- Nivolumab, Antibodies, Monoclonal, Antineoplastic Agents, Brain, Brain Edema, Brain Neoplasms, Child, Female, Glioblastoma, Humans, Fatal Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.